Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immutep (IMMP) reported 81.1% disease-free survival at 12 months in its Phase II EFTISARC-NEO trial for high-risk, resectable soft tissue sarcoma. The study tested eftilagimod alfa with pembrolizumab and radiotherapy before surgery. Of 40 enrolled patients, 38 underwent surgery and were evaluated for survival; eight had disease recurrence by April 30, 2026. The 18-month disease-free survival estimate was also 81.1% but remains immature.
The trial previously met its primary endpoint, with median tumour hyalinisation and fibrosis, changes in tumour tissue, of 51.5%. Exploratory analyses linked higher immune-cell levels in tumours and greater tissue changes after treatment to higher 12-month disease-free survival. Immutep expects more data in CY2027 and targets an H2 CY2027 start for a trial intended to support regulatory approval, subject to regulatory interactions, manufacturing timelines, partnering arrangements and available resources.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointPrimary endpoint was met, with median tumour hyalinisation and fibrosis of 51.5% after treatment.
- Moderate point12-month disease-free survival was 81.1% in the Phase II survival analysis.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Trial intended to support regulatory approval is in preparation, with Immutep targeting initiation in H2 CY2027.
- Minor point12-month local recurrence-free survival was 94.1%.
- Minor point12-month distant metastasis-free survival was 86.2%.
3 minor points
- Minor pointHigher post-treatment tumour lymphocyte levels showed exploratory 12-month disease-free survival of 95.0% above 310 cells/mm² versus 64.9% at lower levels.
- Minor pointGreater treatment-related hyalinisation and fibrosis showed exploratory 12-month disease-free survival of 93.8% above 52% versus 71.4% at lower levels.
- Minor point. Forward-looking: it has not happened yet and may not happen.Additional EFTISARC-NEO data are expected by Immutep in CY2027.
Negative
- Minor point18-month disease-free survival estimate of 81.1% remains immature, with follow-up ongoing.
- Minor pointDisease recurrence occurred in eight of 38 patients evaluated after surgery by April 30, 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.Planned trial start depends on regulatory interactions, manufacturing timelines, partnering arrangements and available resources.
News Explained
At its CTOS 2026 poster, Immutep reported exploratory subgroup results: 12-month DFS was
Key Figures
- 12-month disease-free survival
- 81.1%
- Latest analysis; mature
- 18-month disease-free survival
- 81.1%
- Kaplan-Meier estimate; immature
- 12-month local recurrence-free survival
- 94.1%
- EFTISARC-NEO latest analysis
- 12-month distant metastasis-free survival
- 86.2%
- EFTISARC-NEO latest analysis
- 12-month DFS by post-treatment TIL level
- 95.0% vs. 64.9%
- TIL levels above 310 cells/mm² vs. lower levels
- 12-month DFS by hyalinisation and fibrosis
- 93.8% vs. 71.4%
- Above 52% vs. lower levels
- Patients evaluated for survival
- 38 patients
- Patients who underwent surgery
Previous Clinical trial Reports
-
Earlier report showed improved quality of life after surgery and a 51.5% median tumour hyalinisation/fibrosis result.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
disease-free survival medical
tumour-infiltrating lymphocytes medical
kaplan-meier estimate medical
neoadjuvant medical
orphan drug designation regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Poster presented today at CTOS 2026 expands on the survival data first reported in the abstract (announced 11 November 2026), which showed a 12-month disease-free survival (DFS) of
81.1% in patients with resectable soft tissue sarcoma. - Patients with post-treatment tumour-infiltrating lymphocyte (TIL) levels above 310 cells/mm² had
95.0% 12-month DFS compared with64.9% in patients with lower TIL levels. - Patients with treatment-related hyalinisation and fibrosis greater than
52% had93.8% 12-month DFS compared with71.4% in patients with lower levels. - Results build on previously reported strong pathological responses and further support the potential of efti-based combination therapy.
SYDNEY, AUSTRALIA, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announced new data from the investigator-initiated EFTISARC-NEO Phase II study presented at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting (Poster number P 448).
The study is evaluating Immutep’s eftilagimod alfa (efti) in combination with KEYTRUDA® (pembrolizumab) and radiotherapy before surgery in patients with high-risk, resectable soft tissue sarcoma. Forty patients were enrolled, and 38 patients underwent surgery and were included in the survival evaluation.
The latest analysis currently shows a disease-free survival (DFS) of
Table 1 – Survival results for soft tissue sarcoma patients from EFTISARC-NEO
| Outcome | Latest Analysis |
| 12-month disease-free survival (mature) | |
| 18-month disease-free survival (immature) | |
| 12-month local recurrence-free survival | |
| 12-month distant metastasis-free survival | |
| Median follow-up | 19.1 months |
In addition, exploratory analyses showed that higher levels of tumour-infiltrating lymphocytes (TILs) and greater hyalinisation and fibrosis after treatment may be associated with better DFS. In particular, patients with post-treatment TIL levels above 310 cells/mm² had
These survival and exploratory findings build on previously reported EFTISARC-NEO results in which the trial met its primary endpoint with a median tumour hyalinisation/fibrosis of
Pawel Sobczuk, MD PhD, one of the Principal Investigators of EFTISARC-NEO, said: “These results are highly encouraging for patients with high-risk soft tissue sarcoma, where recurrence remains a major concern despite surgery and radiotherapy. Disease-free survival of approximately
Marc Voigt, CEO of Immutep, said: “With the data to date, EFTISARC-NEO is delivering an increasingly coherent and encouraging picture. The marked difference in outcomes between patients with higher and lower post-treatment immune cell infiltration is especially notable and is consistent with efti’s potential to help generate a stronger anti-tumour immune response. We believe these results strengthen the rationale for further potential clinical development in this indication, where patients remain in need of more effective treatment options.”
The poster is available on the Posters & Publications page of Immutep’s website.
Next Steps
Immutep anticipates reporting additional data from EFTISARC-NEO in CY2027.
Subject to regulatory interactions, manufacturing timelines, partnering arrangements and available resources, the Company is preparing to advance efti into a registration-directed clinical trial in neoadjuvant soft tissue sarcoma, targeting initiation in H2 CY2027.
About EFTISARC-NEO
EFTISARC-NEO is an investigator-initiated, open-label Phase II trial evaluating eftilagimod alfa (efti) in combination with KEYTRUDA® (pembrolizumab) and radiotherapy as neoadjuvant treatment for patients with resectable soft tissue sarcoma. The trial is led by the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland, and is primarily funded by a grant from the Polish Medical Research Agency, with Immutep supplying efti.
The primary endpoint is pathological response, measured as the percentage of tumour hyalinisation/fibrosis at resection. Secondary endpoints include safety, disease-free survival, local recurrence-free survival, distant metastasis-free survival, overall survival, radiological response and health-related quality of life. Forty patients were enrolled, with enrolment completed in January 2025 (ClinicalTrials.gov: NCT06128863).
About Eftilagimod Alfa (efti)
Eftilagimod alfa (efti) is Immutep’s proprietary soluble LAG-3 protein and MHC Class II agonist that activates antigen-presenting cells through the MHC Class II pathway, engaging both innate and adaptive immunity, including the priming of cytotoxic CD8+ T cells and the production of co-stimulatory signals and cytokines. Its favourable safety profile enables combination with anti-PD-(L)1 therapy, radiotherapy and/or chemotherapy. Efti has received Fast Track designation from the U.S. Food and Drug Administration in first-line head and neck squamous cell carcinoma and first-line non-small cell lung cancer, and Orphan Drug Designation in soft tissue sarcoma.
About Immutep
Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding anticipated clinical development, regulatory progress and potential benefits of eftilagimod alfa. These forward-looking statements are based on current expectations, estimates and projections, and involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied in such statements.
Factors that could cause actual results to differ materially include risks associated with clinical trial outcomes, regulatory developments, and the Company’s ability to advance its product candidates.
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Immutep undertakes no obligation to update or revise such statements, except as required by applicable law.
Disclaimer
This announcement has been prepared for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, securities in any jurisdiction.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com
US Investors/Media:
Matthew Beck, astr partners
+1 (917) 415-1750; matthew.beck@astrpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.